This volume of "The Enzymes" features high-caliber thematic articles on the topic of glycosylphosphatidylinositol (GPI) anchoring of proteins.
* Contributions from leading authorities
* Informs and updates on all the latest developments in the field

 TOR, the Target of Rapamycin was discovered a little over ten years ago in a genetic screen in S. cerevisiae in search of mutants resistant to the cytostatic effects of the antimycotic, rapamycin. Recent studies have placed TOR at the interface between nutrient sensing and the regulation of major anbolic and catabolic responses. The editors have gathered the leading figures in the field of TOR and its role in cellular homeostasis and human diseases.

TOR, the Target of Rapamycin was discovered a little over ten years ago in a genetic screen in S. cerevisiae in search of mutants resistant to the cytostatic effects of the antimycotic, rapamycin. Recent studies have placed TOR at the interface between nutrient sensing and the regulation of major anbolic and catabolic responses. The editors have gathered the leading figures in the field of TOR and its role in cellular homeostasis and human diseases.

Yeast genetics began with Winge's 1935 studies of S. cerevisiae in Copenhagen, and afterwards was pursued by Lindegren in the U.S. and Ephrussi in France. Genetic studies in S. pombe were pioneered by Leupold in the 1940s in Switzerland. Within four decades, not without controversies, both yeast species were recognized as essential models in eukaryotic molecular cell biology. In this remarkable volume, Hall and Linder have assembled the reminiscences of many early investigators whose pioneering studies in the years before 1975 brought yeast biology to its current maturity. These illustrated essays about the science, the events and the personalities involved capture a fascinating era, in the informal style made famous by Phage and the Origins of Molecular Biology. This is a book that all scientists interested in the development of modern genetics and molecular biology should have on their shelves.

Cell growth is highly regulated and is controlled by the TOR signaling network. Dysfunction of signaling pathways controlling cell growth results in cells of altered sizes and in turn causes developmental errors and a wide range of pathological conditions. An understanding of the TOR signaling network may lead to novel drugs for the treatment of, for example, cancer, diabetes, inflammation, muscle atrophy, learning disabilities, depression, obesity and aging.

There has been an explosion of knowledge in this area in recent years and this volume provides an in-depth review of our current knowledge of TOR complexes by the leaders in the field.
* Contributions from leading authorities
* Informs and updates on all the latest developments in the field